Medicure Inc. (TSXV: MPH)

Market Cap	9.18M
Revenue (ttm)	20.93M
Net Income (ttm)	-2.63M
Shares Out	10.44M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,200
Open	0.880
Previous Close	0.880
Day's Range	0.880 - 0.880
52-Week Range	0.840 - 1.590
Beta	0.90
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Medicure

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 38
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: MPH